Illumina

Illumina Inc. reported second-quarter profit of $207 million, or $1.35 per share, surpassing Wall Street's $1.23 per share estimate. Revenue reached $1.16 billion, exceeding expectations of $1.12 billion. The company projected full-year earnings of $5.30 to $5.40 per share and revenue of $4.6 billion to $4.64 billion.

The International Human Cell Atlas Consortium is hosting a major meeting in Boston, featuring leaders like Aviv Regev and Eric Lander, as it advances toward publishing its first draft of a comprehensive human cell map. The project faces potential conflict-of-interest concerns due to its reliance on 10x Genomics' technology, which is now competing with other emerging spatial biology tools from companies like Vizgen and Illumina.

Institut Pasteur de Dakar has sequenced the first 40 human whole genomes in Senegal using Illumina and Oxford Nanopore Technologies. The institution launched a clinical laboratory and bioinformatics platform for testing early-onset breast cancer predisposition and rare heritable gene changes. A multidisciplinary research program integrating genomics, infectious diseases, and environmental factors aims to address cancer's growing burden in Senegal and Africa.